Zusammenfassung
Zielsetzung
Darstellung der Wertigkeit der Bild gebenden Verfahren für die Diagnostik von neuroendokrinen Tumoren (NET) des gastroenteropankreatischen Systems.
Methodik
Analyse des Stellenwerts von Ultraschall (US), Computertomographie (CT) und Magnetresonanztomographie (MRT) unter Berücksichtigung diagnostischer Strategien und Ergebnisse der Literatur.
Ergebnisse
Für die Primärtumor- und Ausbreitungsdiagnostik wurden in Abhängigkeit der Lokalisation Sensitivitäten für den US von ca. 60%, den EUS von über 90% beschrieben. Die MRT weist für die Pankreasdiagnostik eine gegenüber der CT höhere Sensitivität (75–100% vs. 72–82%) auf und ist im Nachweis einer Lebermetastasierung führend. Einschränkungen bestehen in der Diagnostik von NET des Darmtrakts. Insbesondere zur Primärtumorsuche sind hier die Somatostatinrezeptorszintigraphie und endoskopische Verfahren als vorrangig zu betrachten.
Schlussfolgerung
Eine suffiziente Diagnostik von NET bedarf der Kombination aus radiologischen, nuklearmedizinischen und endoskopischen Verfahren.
Abstract
Objective
Comparison of the diagnostic value of imaging modalities in the detection of gastroenteropancreatic neuroendocrine tumors (NET).
Methods
Analysis of the value of ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and diagnostic strategies according to the current literature.
Results
Depending on the localization of primaries and metastases, a sensitivity of 60% and 90% is described for US and EUS, respectively. Concerning pancreatic lesions and liver metastases, MRI is more sensitive than CT (75–100% vs 72–82%). Concerning lesions of the bowel, these modalities are subject to limitations. In this field somatostatin receptor scintigraphy and endoscopic procedures are superior.
Conclusion
A sufficient diagnostic strategy for NET often requires a combination of various imaging modalities.
Literatur
Amthauer H, Ruf J, Bohmig M, Lopez-Hanninen E, Rohlfing T, Wernecke KD, Plockinger U, Gutberlet M, Lemke AJ, Steinmuller T, Wiedenmann B, Felix R (2004) Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit? Eur J Nucl Med Mol Imaging 31:342–348
Bansal R, Tierney W, Carpenter S, Thompson N, Scheiman JM (1999) Cost effectiveness of EUS for preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc 49:19–25
Bartynski WS, Lin L (1997) Dynamic and conventional spin-echo MR of pituitary microlesions. Am J Neuroradiol 18:965–967
Bottger TC, Weber W, Beyer J, Junginger T (1990) Value of tumor localization in patients with insulinoma. World J Surg 14:107–112
Gines A, Vazquez-Sequeiros E, Soria MT, Clain JE, Wiersema MJ (2002) Usefulness of EUS-guided fine needle aspiration (EUS-FNA) in the diagnosis of functioning neuroendocrine tumors. Gastrointest Endosc 56:291–296
Grama D, Skogseid B, Wilander E, Eriksson B, Martensson H, Cedermark B, Ahren B, Kristofferson A, Oberg K, Rastad J (1992) Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment. World J Surg 16:611–618
Ichikawa T, Peterson MS, Federle MP, Baron RL, Haradome H, Kawamori Y, Nawano S, Araki T (2000) Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 216:163–171
King CM, Reznek RH, Dacie JE, Wass JA (1994) Imaging islet cell tumours. Clin Radiol 49:295–303
Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U (2003) Evaluation of positron emission tomography imaging using [68 Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5(1):42–48
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC, et al. (1993): Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731
Lamberts SW, Hofland LJ, Lely AJ, de Herder WW (1998) Somatostatin receptor expression in multiple endocrine neoplasia and in von Hippel-Lindau disease. J Intern Med 243:569–571
Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M, le Guludec D (1997) Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 38:853–858
Lopez Hanninen E, Vogl TJ, Steinmuller T, Ricke J, Neuhaus P, Felix R (2000) Preoperative contrast-enhanced MRI of the parathyroid glands in hyperparathyroidism. Invest Radiol 35:426–430
Lopez Hanninen E, Amthauer H, Hosten N, Ricke J, Bohmig M, Langrehr J, Hintze R, Neuhaus P, Wiedenmann B, Rosewicz S, Felix R (2002) Prospective evaluation of pancreatic tumors: accuracy of MR imaging with MR cholangiopancreatography and MR angiography. Radiology 224:34–41
Modlin IM, Esterline W, Kim H, Goldenring JR (1991) Enterochromaffin-like cells and gastric argyrophil carcinoidosis. Acta Oncol 30:493–498
Modlin IM, Tang LH (1997) Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology 112:583–590
Öberg K (1999) Neurendocrine gastrointestinal tumors – a condensed overview of diagnosis and treatment. Ann Oncol 10:3–8
Owen NJ, Sohaib SA, Peppercorn PD, Monson JP, Grossman AB, Besser GM, Reznek RH (2001) MRI of pancreatic neuroendocrine tumours. Br J Radiol 74:968–973
Pape UF, Böhmig M, Tiling N, Wiedenmann B (2000) Diagnostik und Therapie gastroenteropankreatischer neuroendokriner Tumore aus internistischer Sicht. Onkologe 6:624–633
Pfannenberg AC, Eschmann SM, Horger M, Lamberts R, Vonthein R, Claussen CD, Bares R (2003) Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 30):835–843
Ricke J, Klose KJ (2000) Imaging procedures in neuroendocrine tumours. Digestion 62 Suppl 1:39–44
Ricke J, Hanninen EL, Amthauer H, Lemke A, Felix R (2000) Assessment of the vascularization of neuroendocrine tumors by stimulated acoustic emission of SH U 508A ultrasound contrast agent and color or power Doppler sonography. Invest Radiol 35:253–259
Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B (2001) Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 37:8–17
Rindi G, Capella C, Solcia E (1998) Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors. J Mol Med 76:413–420
Rösch T, Lightdale CJ, Botet JF, Boyce GA, Sivak MV, Yasuda K, Heyder N, Palazzo L, Dancygier H, Schusdziarra V, Classen M (1992) Endosonograpic localization of pancreatic endocrine tumors. New Engl J Med 326:1721–1726
Rösch T, Kassem AM (1999) Endoskopischer Ultraschall, in P. Frühmorgen: Gastroenterologische Endoskopie. Ein Leitfaden zur Diagnostik und Therapie. Springer, Heidelberg
Rogalla P, Meiri N, Ruckert JC, Hamm B (2000) Colonography using multislice CT. Eur J Radiol 36:81–85
Schima W, Fugger R (2002) Evaluation of focal pancreatic masses: comparison of mangafodipir-enhanced MR imaging and contrast-enhanced helical CT. Eur Radiol 12:2998–3008
Semelka RC, John G, Kelekis NL, Burdeny DA, Ascher SM (1996) Small bowel neoplastic disease: demonstration by MRI. J Magn Reson Imaging 6:855–860
Semelka RC, Custodio CM, Cem Balci N, Woosley JT (2000) Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging 11:141–148
Sugimoto E, Lorelius LE, Eriksson B, Oberg K (1995) Midgut carcinoid tumours. CT appearance. Acta Radiol 36:367–371
Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, Sutliff VE, Jensen RT (1997) Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112:335–347
Thiele J, Kloppel R, Schulz HG (1993) CT-Sellink--a new method of evaluating the intestinal wall Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 159:213–217
Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB (2000) Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 214:483–490
Van Hoe L, Gryspeerdt S, Marchal G, Baert AL, Mertens L (1995) Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images. AJR Am J Roentgenol 165:1437–1439
Vick C, Zech CJ, Hopfner S, Waggershauser T, Reiser M (2003) Bildgebung bei neuroendokrinen Tumoren des Pankreas. Radiologe 43:293–300
Vogl TJ, Schwarz W, Blume S, Pietsch M, Shamsi K, Franz M, Lobeck H, Balzer T, del Tredici K, Neuhaus P, Felix R, Hammerstingl RM (2003) Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. Eur Radiol 13:262–272
Wiedenmann B, Jensen RT, Mignon M, Modlin CI, Skogseid B, Doherty G, Öberg K (1998) Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 22:309–318
Zimmer T, Ziegler K, Liehr RM, Stolzel U, Riecken EO, Wiedenmann B (1994) Endosonography of neuroendocrine tumors of the stomach, duodenum, and pancreas. Ann N Y Acad Sci 733:425–436
Zimmer T, Stolzel U, Bader M, Koppenhagen K, Hamm B, Buhr H, Riecken EO, Wiedenmann B (1996) Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 39:562–568
Interessenkonflikt:
Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Amthauer, H., Ruf, J., Rösch, T. et al. Bildgebung bei neuroendokrinen Tumoren. Onkologe 10, 588–597 (2004). https://doi.org/10.1007/s00761-004-0717-0
Issue Date:
DOI: https://doi.org/10.1007/s00761-004-0717-0